Introduction
Methods
Patients
Clinicopathological characteristics
Statistical analysis
Results
Patients, clinico-pathological factors and features associated with non-resectability
Details of the patients undergoing potentially curative esophagectomy
Disease-free survival | Overall survival | ||||
---|---|---|---|---|---|
Clinicopathological variables | Frequency n (%) | 5-year survival rate (%) | p-value | 5-year survival rate (%) | p-value |
T stage | |||||
CR | 22 (7.5) | 100.0 | < 0.001 | 100.0 | < 0.001 |
1 | 74 (25.2) | 84.0 | 80.0 | ||
2 | 32 (10.9) | 45.5 | 40.9 | ||
3 | 144 (49.0) | 37.0 | 33.8 | ||
4 | 22 (7.5) | 0.0 | 0.0 | ||
N stage | |||||
0 | 145 (49.3) | 72.9 | < 0.001 | 69.5 | < 0.001 |
1 | 80 (27.2) | 35.6 | 31.1 | ||
2 | 48 (16.3) | 11.1 | 5.6 | ||
3 | 21 (7.1) | 11.1 | 11.1 | ||
Tumour Stage | |||||
CR | 22 (7.5) | 100.0 | < 0.001 | 100.0 | < 0.001 |
I | 82 (27.9) | 72.7 | 69.7 | ||
II | 60 (20.4) | 63.9 | 58.3 | ||
III | 130 (44.2) | 20.3 | 16.9 | ||
Differentiation | |||||
Well/Moderate | 175 (59.5) | 58.0 | 0.002 | 53.1 | 0.005 |
Poor | 119 (40.5) | 30.0 | 28.0 | ||
Vascular invasion | |||||
No | 153 (52.0) | 68.8 | < 0.001 | 67.2 | < 0.001 |
Yes | 141 (48.0) | 26.9 | 20.9 | ||
Lymph node sample | |||||
≥ 15 | 154 (52.4) | 48.8 | 0.667 | 45.1 | 0.631 |
< 15 | 140 (47.6) | 44.9 | 40.8 | ||
R status | |||||
0 | 179 (60.9) | 62.2 | < 0.001 | 55.4 | 0.002 |
1 | 115 (39.1) | 28.1 | 28.1 | ||
Perioperative chemotherapy | |||||
No | 87 (39.6) | 65.8 | 0.007 | 65.8 | 0.001 |
Yes | 207 (70.4) | 39.8 | 34.4 | ||
0 |
Disease-free survival | Overall survival | ||||
---|---|---|---|---|---|
Clinico-pathological variables | Frequency n (%) | 5-Year survival rate (%) | p-value | 5-year survival rate (%) | p-value |
Age (years) | 0.991 | ||||
< 65 | 100 (34.0) | 47.2 | 0.581 | 44.4 | |
65–75 | 141 (48.0) | 43.1 | 43.1 | ||
> 75 years | 53 (18.0) | 54.1 | 43.2 | ||
Sex | 0.714 | ||||
Female | 44 (15.0) | 52.6 | 0.617 | 47.4 | |
Male | 250 (85.0) | 46.4 | 42.9 | ||
White Cell count | 0.876 | ||||
Low | 20 (6.8) | 50.0 | 0.878 | 50.0 | |
Normal | 269 (91.5) | 47.5 | 43.3 | ||
High | 5 (1.7) | 33.3 | 33.3 | ||
Neutrophil count | 0.743 | ||||
Low | 280 (95.2) | 47.2 | 0.893 | 43.2 | |
High | 14 (4.8) | 50.0 | 50.0 | ||
Lymphocyte count | 0.501 | ||||
Low | 44 (15.0) | 47.1 | 0.623 | 41.2 | |
Normal | 242 (82.3) | 46.3 | 42.6 | ||
High | 8 (2.7) | 66.7 | 66.7 | ||
Platelet count | 0.042 | ||||
Low | 286 (97.3) | 46.1 | 0.065 | 42.2 | |
High | 8 (2.7) | 100.0 | 100.0 | ||
C-Reactive Protein | 0.585 | ||||
Normal | 247 (84.0) | 49.1 | 0.355 | 44.5 | |
High | 47 (16.0) | 38.1 | 38.1 | ||
Albumin | 0.984 | ||||
Normal | 245 (83.3) | 47.8 | 0.760 | 43.5 | |
Low | 49 (16.7) | 43.8 | 43.8 | ||
Derivative markers | |||||
Neutrophil–Lymphocyte Ratio | 0.137 | ||||
Low | 263 (89.5) | 45.3 | 0.233 | 49.6 | |
High | 31 (10.5) | 28.6 | 28.6 | ||
Neutrophil–Platelet Score | 0.147 | ||||
Low | 273 (92.9) | 45.9 | 0.229 | 41.8 | |
Intermediate | 20 (6.8) | 66.7 | 66.7 | ||
High | 1 (0.3) | N/A | N/A | ||
Platelet–Lymphocyte Ratio | 0.765 | ||||
Low | 137 (46.6) | 48.4 | 0.804 | 42.2 | |
High | 157 (53.4) | 46.3 | 44.8 | ||
Modified Glasgow prognostic Score | 0.593 | ||||
Low | 247 (84.0) | 49.1 | 0.452 | 44.5 | |
Intermediate | 28 (9.5) | 30.8 | 30.8 | ||
High | 19 (6.5) | 50.0 | 50.0 |
Relationships between the SIR, clinico-pathological factors and survival
Univariable | Multivariable | Univariable | Multivariable | |||||
---|---|---|---|---|---|---|---|---|
Disease-free survival | Overall survival | |||||||
Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
Age (< 65/65–75 / > 75) | 1.05 (0.78–1.41) | 0.762 | 0.92 (0.71–1.20) | 0.530 | ||||
Gender (female/male) | 1.09 (0.58–2.05) | 0.792 | 1.10 (0.63–1.93) | 0.742 | ||||
pT stage (1/2/3/4) | 2.01 (1.56–2.58) | < 0.001 | 0.522 | 2.23 (1.74–2.86) | < 0.001 | 0.267 | ||
pN stage (0/1/2/3) | 2.07 (1.69–2.54) | < 0.001 | 0.066 | 2.20 (1.84–2.63) | < 0.001 | 1.67 (1.33–2.10) | < 0.001 | |
pTNM stage (I/II/III) | 2.63 (1.96–3.54) | < 0.001 | 1.51 (1.00–2.29) | 0.051 | 2.75 (2.09–3.63) | < 0.001 | 0.362 | |
Differentiation (well/moderate/poor) | 2.21 (1.44–3.39) | < 0.001 | 0.182 | 2.59 (1.76–3.81) | < 0.001 | 1.58 (1.05–2.36) | 0.027 | |
Vascular invasion (no/yes) | 5.26 (3.22–8.60) | < 0.001 | 3.03 (1.75–5.26) | < 0.001 | 4.60 (2.98–7.11) | < 0.001 | 2.87 (1.82–4.52) | < 0.001 |
R status (0/1) | 2.49 (1.62–3.82) | < 0.001 | 0.574 | 3.29 (2.34–4.86) | < 0.001 | 0.059 | ||
Peri-operative chemotherapy (no/yes) | 2.00 (1.19–3.38) | 0.009 | 0.073 | 1.66 (1.06–2.61) | 0.027 | 0.111 | ||
C-reactive protein (normal/high) | 1.94 (1.17–3.20) | 0.010 | 0.504 | 1.94 (1.23–3.06) | 0.004 | 0.363 | ||
mGPS (0/1/2) | 1.50 (1.10–2.05) | 0.011 | 0.839 | 1.48 (1.11–1.98) | 0.008 | 0.815 | ||
NLR (low/high) | 3.08 (1.81–5.24) | < 0.001 | 3.63 (2.11–6.24) | < 0.001 | 2.39 (1.44–3.97) | 0.001 | 2.66 (1.58–4.50) | < 0.001 |
Clinico-pathological factors | NLR low n (%) | NLR high n (%) | p-value |
---|---|---|---|
Age (years) | 0.538 | ||
< 65 | 88 (33.5) | 12 (38.7) | |
65–75 | 129 (49.0) | 12 (38.7) | |
> 75 years | 46 (17.5) | 7 (22.6) | |
Sex | 0.848 | ||
Female | 39 (14.8) | 5 (16.1) | |
Male | 224 (85.2) | 26 (83.9) | |
T stage | 0.150 | ||
CR | 17 (6.5) | 5 (16.1) | |
1 | 70 (26.6) | 4 (12.9) | |
2 | 28 (10.6) | 4 (12.9) | |
3 | 127 (48.3) | 17 (54.8) | |
4 | 21 (8.0) | 1 (3.2) | |
N stage | 0.993 | ||
0 | 129 (49.0) | 16 (51.6) | |
1 | 72 (27.4) | 8 (25.8) | |
2 | 43 (16.3) | 5 (16.1) | |
3 | 19 (7.2) | 2 (6.5) | |
Tumour stage | 0.213 | ||
CR | 17 (6.5) | 5 (16.1) | |
I | 76 (28.9) | 6 (19.4) | |
II | 53 (20.2) | 7 (22.6) | |
III | 117 (44.5) | 13 (41.9) | |
Differentiation | 0.549 | ||
Well/moderate | 155 (58.9) | 20 (64.5) | |
Poor | 108 (41.1) | 11 (35.5) | |
Vascular invasion | 0.960 | ||
No | 137 (52.1) | 16 (51.6) | |
Yes | 126 (47.9) | 15 (48.4) | |
Lymph node sample | 0.018 | ||
≥ 15 | 144 (54.8) | 10 (32.3) | |
< 15 | 119 (45.2) | 21 (67.7) | |
R status | 0.466 | ||
0 | 162 (61.6) | 17 (54.8) | |
1 | 101 (38.4) | 14 (45.2) | |
Peri-operative chemotherapy | 0.031 | ||
No | 83 (31.6) | 4 (12.9) | |
Yes | 180 (68.4) | 27 (87.1) | |
White cell count | < 0.001 | ||
Low | 18 (6.8) | 2 (6.5) | |
Normal | 244 (92.8) | 25 (80.6) | |
High | 1 (0.4) | 4 (12.9) | |
Neutrophil count | < 0.001 | ||
Low | 261 (99.2) | 19 (61.3) | |
High | 2 (0.8) | 12 (38.7) | |
Lymphocyte count | < 0.001 | ||
Low | 24 (9.1) | 20 (64.5) | |
Normal | 231 (87.8) | 11 (35.5) | |
High | 8 (3.0) | 0 (0.0) | |
Platelet count | 0.177 | ||
Low | 257 (97.7) | 29 (93.5) | |
High | 6 (2.3) | 2 (6.5) | |
CRP | < 0.001 | ||
Normal | 230 (87.5) | 17 (54.8) | |
High | 33 (12.5) | 14 (45.2) | |
Albumin | < 0.001 | ||
Normal | 227 (86.3) | 18 (58.1) | |
Low | 36 (13.7) | 13 (41.9) | |
Modified Glasgow Prognostic Score | < 0.001 | ||
0 | 230 (87.5) | 17 (54.8) | |
1 | 23 (8.7) | 5 (16.1) | |
2 | 10 (3.8) | 9 (29.0) | |
Neutrophil-Platelet Score | < 0.001 | ||
Low | 255 (97.0) | 18 (58.1) | |
Intermediate | 8 (3.0) | 12 (38.7) | |
High | 0 (0.0) | 1 (3.2) | |
Platelet-Lymphocyte ratio | < 0.001 | ||
Low | 136 (51.7) | 1 (3.2) | |
High | 127 (48.3) | 30 (96.8) |